Rigel Pharmaceuticals, Inc. (RIGL)
Chart Events
Performance Outlook
| Previous Close | 1.5400 |
| Open | 1.5100 |
| Bid | 1.5600 x 1200 |
| Ask | 1.5700 x 1200 |
| Day's Range | 1.5000 - 1.5900 |
| 52 Week Range | 0.6400 - 4.2400 |
| Volume | |
| Avg. Volume | 6,581,545 |
| Market Cap | 272.217M |
| Beta (5Y Monthly) | 1.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4970 |
| Earnings Date | Oct 31, 2022 - Nov 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.64 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for RIGL
Related Research
- Rigel Pharmaceuticals, Inc.Analyst Report: Pfizer Inc.Pfizer is a leading global developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs, treatments for rare diseases, and vaccines.RatingFair ValueEconomic Moat4 days agoArgus Research
- Benzinga
Rigel Pharma Expands Blood Cancer Portfolio With Forma Therapeutics Licensing Pact
Rigel Pharmaceuticals Inc (NASDAQ: RIGL) and Forma Therapeutics Inc (NASDAQ: FMTX) entered into an exclusive, worldwide license agreement to develop, manufacture and commercialize olutasidenib. Olutasidenib is an oral, small molecule inhibitor of mIDH1 being investigated for relapsed/refractory acute myeloid leukemia (R/R AML) and other malignancies. The FDA has accepted Forma's marketing application for olutasidenib with the Prescription Drug User Fee Act target date of February 15, 2023. Relat
- Zacks
Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of 33.33% and 26.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter ended June 30, 2022, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
